Orexo appoints Peter Edman CSO
This article was originally published in Scrip
Orexo, a pharma company developing pain and inflammation treatments, has appointed Dr Peter Edman chief scientific officer, effective 1 January 2012. Dr Edman has been CSO and head of R&D at Swedish Orphan Biovitrum since 2008, and previously served at Pharmacia, Swedish Medical Product Agency and AstraZeneca.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.